What is Cytek Biosciences, Inc.'s D&A?

Cytek Biosciences, Inc. (CTKB) reported D&A of $1.87M in Q1 2026.

How has Cytek Biosciences, Inc.'s D&A changed year-over-year?

Cytek Biosciences, Inc.'s D&A decreased by 0.5% year-over-year, from $1.88M to $1.87M.

What is the long-term trend for Cytek Biosciences, Inc.'s D&A?

Over 4 years (2021 to 2025), Cytek Biosciences, Inc.'s D&A has grown at a 57.2% compound annual growth rate (CAGR), from $1.24M to $7.58M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Cytek Biosciences, Inc. CTKB D&A

D&A at other companies

Becton, Dickinson and CompanyBDX

$563M-0.7%

DanaherDHR

$193M+6.6%

Fulgent Genetics, Inc.FLGT

$6M+1.4%

10x Genomics, Inc.TXG

$9.96M+24.1%

TEC

Bio-TechneTECH

$24.17M-12.3%

RevvityRVTY

$105.06M+7.8%

Other financials

Income statement

See full

Revenue$44.1M+6.5%

Gross profit$21.3M+5.4%

Operating income-$18.5M-23.3%

Net income-$18.9M-65.5%

EPS (diluted)-$0.15-66.7%

Balance sheet

See full

Cash & equivalents$31.8M-66.6%

Total debt$16.8M+40.9%

Total equity$327.6M-13.7%

Total assets$449.1M-6.9%

Cash flow

See full

Operating cash flow-$2.7M-2,089%

CapEx$2.2M+155%

Free cash flow-$4.9M-403%

Valuation

See full

Market cap$577.27M+54.5%

Enterprise value$562.23M+93.7%

P/S2.8×+0.9×

Profitability

See full

Gross margin51.7%-3.2pp

Operating margin-21.5%—

Net margin-36.2%—

FCF margin-6.2%-15.1pp

Returns & leverage

See full

Return on equity-20.9%—

Debt / equity0.1×0.0×

Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s D&A?: Cytek Biosciences, Inc. (CTKB) reported D&A of $1.87M in Q1 2026.
How has Cytek Biosciences, Inc.'s D&A changed year-over-year?: Cytek Biosciences, Inc.'s D&A decreased by 0.5% year-over-year, from $1.88M to $1.87M.
What is the long-term trend for Cytek Biosciences, Inc.'s D&A?: Over 4 years (2021 to 2025), Cytek Biosciences, Inc.'s D&A has grown at a 57.2% compound annual growth rate (CAGR), from $1.24M to $7.58M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.